Juneau, Alaska (KINY) - Due to a limited supply of monoclonal antibody therapeutics nationwide and Juneau’s rapidly increasing COVID-19 case count, Bartlett Regional Hospital is implementing strict criteria for therapy administration.
The criteria outline that the treatment will be for individuals with immunocompromising conditions, those who have received a solid organ transplant and are taking medicine to suppress the immune system, and unvaccinated individuals who are pregnant, over 75, or over 65 with certain risk factors.
The latest criteria for therapy administration are based on draft recommendations of the statewide Crisis Care Committee for the distribution of the type of monoclonal antibody. CBJ Deputy Manager Robert Barr said out of the three monoclonal antibodies that are being produced by three different manufacturers to administer to people who get COVID, only one will continue to be effective against omicron, Sotrovimab.
"So we can't use two of the three that we have been using, and so that one, as you might imagine, is starting to become in short supply," he said. "And it's not only in short supply, but we're also not expecting to get a whole lot of doses of that in the future."
The next statewide allocation will be around 40 to 50 doses for the whole state, according to Barr. "We would go through that much in a week normally, just in Juneau," he said.
Regional Hospital has been administering this therapy since January 2021.